Intellectual property offices of US/JP/AU/TW approved patent of LXP5268 for tumor treatment.
Patent NO. of US:US 10045962 B2
Patent NO. of JP:JP 6539345 B2
Patent NO. of AU:AU 2015335391 B2
Patent NO. of TW:I 621434
Results of preclinical experiment show that combined use of LXP 5268 and chemotherapeutic drugs can effectively and synergistically inhibit triple-negative breast cancer, and can significantly reduce the tumor volume.
In August 2021, a clinical trial of LXP5268 as an add-on neoadjuvant treatment in patients with triple-negative breast cancer (TNBC) has been conducted at the Central Taiwan Medical Center. The type of clinical trial is a Proof of concept (PoC) initiated by an Investigator-initiated the trial by the attending physician. The subject of the case was triple-negative breast cancer (TNBC).
We estimate the trial completion time will be in June 2023. The Design of clinical trial for LXP5268 will based on the result of PoC trial.